Gaithersburg, United States
Georgiamune Inc., founded in 2014, operates at the intersection of biotechnology, health care, and wellness. This U.S.-based clinical-stage immunotherapeutic biotechnology firm is driving innovation by reprogramming immune signaling pathways, a strategy aimed at redefining immune system responses to combat an array of diseases.
The company has garnered attention for its pioneering work in immune therapeutics targeting cancer and autoimmune diseases. By leveraging groundbreaking scientific discoveries, Georgiamune aims to restore immune balance, setting a new standard in therapeutic development.
Recently, the company secured a $75.00M Series A investment on 09 August 2023. This funding round included support from reputable investors such as BioVentures Investors, General Catalyst, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Parker Institute for Cancer Immunotherapy, and Mubadala Capital Ventures. Their backing signifies strong confidence in Georgiamune's potential to revolutionize immunotherapeutics.
Adaptive Biotechnologies Corp.